NGS Services Market
Report Code
BT 5526
Published in
Oct, 2026, By MarketsandMarkets™
NGS Services Market Size by Type (Presequencing [Sample Prep, Quality Control], Sequencing [RNA, ChIP, Whole Genome], Bioinformatics), Workflow, Application (Diagnostics, Cancer, Drug Discovery, Pharmacogenomic), End User, Region - Global Forecast to 2031
$3.96B
MARKET SIZE, 2026
$9.37B
MARKET SIZE, 2031
18.8%
CAGR (2026-2031)
2026-2031
FORECAST PERIOD
NGS SERVICES MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global NGS services market is projected to grow from USD 3.96 billion in 2026 to USD 9.37 billion by 2031, at a CAGR of 18.8% during the forecast period. The market was valued at USD 3.55 billion in 2025. The NGS services market is growing, driven by increasing outsourcing of sequencing workflows, expansion of population genomics programs, rising use of NGS in clinical research, and growing demand for advanced genomic analysis across drug discovery, diagnostics, and precision medicine. Wider adoption of whole-genome sequencing, exome and targeted sequencing, RNA sequencing, de novo sequencing, ChIP sequencing, and methyl sequencing is supporting demand across research and clinical applications. Additionally, growing adoption of long-read sequencing services, customized NGS workflows, and integrated bioinformatics support is expanding the market. Increasing demand for data analysis, visualization, interpretation, and storage services is also strengthening the role of end-to-end NGS service providers.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 3.55 Billion
Current Market Size (2026): USD 3.96 Billion
Forecast Market Size (2031): USD 9.37 Billion
CAGR (2026-2031): 18.8% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for the largest share of 40.9% of the NGS services market in 2025.
Type Leader: Sequencing services accounted for the largest share of 75.6% of the NGS services market in 2025.
Workflow Leader: Sequencing accounted for the largest share of 84.5% of the NGS services market in 2025.
Application Leader: Diagnostic applications accounted for the largest share of 47.7% of the NGS services market in 2025. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Growth in North America is supported by advanced genomics infrastructure, strong pharmaceutical and biotechnology R&D, widespread outsourcing of sequencing workflows, and growing use of NGS in clinical research, precision medicine, and population genomics. Demand is also driven by whole-genome sequencing, exome and targeted sequencing, RNA sequencing, de novo sequencing, ChIP sequencing, and methyl sequencing across research and clinical applications. The growing use of NGS services in cancer diagnostics, infectious disease testing, reproductive health, and other molecular diagnostic applications supports market growth.
Key players include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), and Eurofins Scientific (Luxembourg), given their strong market share and service footprint.
Emerging market players include Novogene Co., Ltd. (China), GenScript (US), and Psomagen (US), which have secured strong footholds in specialized niche areas.
The NGS services market is growing due to increasing outsourcing of sequencing workflows, expansion of population genomics programs, rising use of NGS in clinical research and precision medicine, and growing demand for long-read sequencing, customized NGS services, and advanced bioinformatics support.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The NGS services market is shifting from conventional sequencing and standardized bioinformatics toward more specialized, integrated, and clinically relevant service models. Established revenue sources such as whole-genome sequencing, whole-exome sequencing, RNA sequencing, targeted sequencing, metagenomics, and routine data analysis remain important. However, future growth is expected to come increasingly from single-cell and spatial sequencing, multi-omics workflows, AI-enabled bioinformatics, clinical-grade genomic testing, and customized large-scale sequencing programs. Pharmaceutical and biotechnology companies, academic and research institutes, and hospitals and clinical laboratories are seeking faster biomarker discovery, high-quality genomic data, shorter sample-to-result timelines, scalable sequencing capacity, and secure genomic reporting. These evolving requirements are encouraging service providers to strengthen sequencing, bioinformatics, interpretation, and compliance capabilities. As a result, NGS services are expected to support improved patient stratification, greater diagnostic precision, reduced repeat testing, cost-efficient access to advanced genomic testing, and wider adoption of precision medicine.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
Growing outsourcing of NGS workflows
-
Expansion of population genomics programs
RESTRAINTS
Impact
Level
Level
-
Decreasing costs of benchtop NGS systems/sequencers
-
Managing turnaround time and capacity utilization
OPPORTUNITIES
Impact
Level
Level
-
Growing adoption of long-read sequencing services
-
Rising demand for customized NGS services
CHALLENGES
Impact
Level
Level
-
Managing, analyzing, and interpreting large volumes of NGS data
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Growing outsourcing of NGS workflows
Pharmaceutical and biotechnology companies, research institutes, and clinical laboratories increasingly outsource NGS workflows to access advanced sequencing platforms, skilled personnel, scalable capacity, and bioinformatics expertise without major infrastructure investment.
Restraint: Decreasing costs of benchtop NGS systems/sequencers
Falling prices of benchtop sequencers are making in-house sequencing more affordable for smaller laboratories and research centers. This can reduce outsourcing for routine, targeted, and lower-volume sequencing projects.
Opportunity: Growing adoption of long-read sequencing services
Long-read sequencing is gaining traction for structural variant analysis, complex genome assembly, and full-length transcript profiling. Limited in-house access to these platforms creates opportunities for specialized NGS service providers.
Challenge: Managing, analyzing, and interpreting large volumes of NGS data
NGS generates large, complex datasets that require robust computing infrastructure, advanced bioinformatics, and skilled interpretation. Managing these requirements can increase project complexity, cost, and turnaround time.
NGS SERVICES MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Commercial NGS services covering clinical whole-genome sequencing, exome sequencing, RNA sequencing, targeted sequencing, 16S microbiome profiling, and metagenomics for clinical research, precision medicine, and microbial studies. | Integrated sequencing and bioinformatics | CAP/CLIA-validated clinical options | Customizable workflows for diverse applications |
 |
WGS, WES, transcriptome, metagenome, epigenome, and single-cell sequencing services used in disease research, biomarker discovery, precision medicine, population studies, and microbiome analysis. Services include sequencing and downstream bioinformatics. | Broad multi-omics service portfolio | High-throughput sequencing capacity | End-to-end sequencing and data analysis support |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The NGS services market ecosystem comprises technology & consumables suppliers, service providers, end users, and regulatory authorities. Technology & consumables suppliers such as Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), QIAGEN (Germany), and PacBio (US) support sequencing workflows through platforms, reagents, library preparation solutions, and related consumables. Service providers including Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Oxford Nanopore Technologies (UK), and BGI Group (China) offer sequencing, customized NGS workflows, and genomic data analysis services across research and clinical applications. Regulatory authorities such as the US FDA, CDSCO, MHRA, and relevant Canadian agencies set requirements for clinical testing, data quality, laboratory practices, and genomic research. End users, including pharmaceutical and biotechnology companies, hospitals and clinical laboratories, and academic and research institutes, use NGS services for drug discovery, biomarker research, cancer diagnostics, infectious disease testing, population genomics, and precision medicine.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
NGS Services Market, By Type
In 2025, sequencing services dominated the NGS services market. Strong demand for whole-genome sequencing, whole-exome sequencing, RNA sequencing, targeted sequencing, de novo sequencing, ChIP sequencing, and methyl sequencing supports this leadership. These services are widely used across drug discovery, population genomics, clinical research, diagnostics, and translational studies. Growing outsourcing of sequencing workflows, rising demand for high-throughput analysis, and the need for access to advanced platforms continue to support the segment’s leading position.
NGS Services Market, By Application
In 2025, diagnostic applications dominated the NGS services market, supported by the growing use of sequencing in cancer diagnostics, infectious disease testing, reproductive health, and other molecular diagnostic applications. NGS enables sensitive detection of genomic alterations and supports broad molecular profiling from limited samples. Increasing adoption of precision diagnostics, growing use of sequencing in clinical workflows, and rising demand for earlier and more accurate disease characterization continue to strengthen demand across diagnostic applications.
NGS Services Market, By End User
In 2025, academic & research institutes dominated the NGS services market due to their extensive use of sequencing across genomics research, disease biology, biomarker discovery, population studies, and translational research. These institutes increasingly outsource NGS workflows to access advanced sequencing platforms, specialized technical expertise, scalable laboratory capacity, and bioinformatics support. Strong research funding, expanding multi-omics studies, and growing adoption of whole-genome, RNA, and targeted sequencing continue to drive demand across this end-user group.
REGION
Asia Pacific to be fastest-growing region in global NGS services market during forecast period
The Asia Pacific NGS services market is expected to register the highest CAGR during the forecast period, supported by rapid expansion of genomics infrastructure, increasing outsourcing of sequencing workflows, and growing use of NGS in clinical research. China, India, Japan, and South Korea are investing in sequencing centers, population genomics programs, precision medicine initiatives, and academic-industry collaborations. This is creating strong demand for whole-genome sequencing, RNA sequencing, targeted sequencing, and advanced bioinformatics services. The region also benefits from an expanding base of CROs, clinical laboratories, and specialized sequencing service providers that offer scalable and cost-efficient support. Rising research activity in oncology, rare diseases, infectious diseases, reproductive health, and population genomics is further accelerating adoption of NGS services across Asia Pacific.
NGS SERVICES MARKET: COMPANY EVALUATION MATRIX
In the NGS services market company evaluation matrix, Illumina, Inc. (US) is positioned as a star player due to its strong presence across sequencing services, population genomics programs, clinical research support, and genomic data analysis. The company supports whole-genome sequencing, targeted sequencing, RNA sequencing, and large-scale genomics projects across pharmaceutical, biotechnology, healthcare, and research customers. Its sequencing expertise, global customer base, scalable project capabilities, and strong bioinformatics support strengthen its market position. Labcorp (US) is an emerging leader, supported by its growing NGS capabilities in biopharma laboratory services and clinical genomics. The company provides sequencing and molecular testing services for biomarker development, oncology research, clinical trials, and precision medicine applications. Its established laboratory network, access to clinical samples, and ability to integrate genomic testing with broader drug development services are strengthening its position in the NGS services market.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Illumina, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- Eurofins Scientific (Luxembourg)
- Azenta US Inc. (US)
- BGI Group (China)
- Revvity (US)
- Agilent Technologies, Inc. (US)
- PacBio (US)
- Oxford Nanopore Technologies plc (UK)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- LGC Limited (UK)
- WuXi Biologics (China)
- QIAGEN (Germany)
- Labcorp (US)
- IQVIA (US)
- Twist Bioscience (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | 3.55 Billion |
| Market Forecast in 2026 (Value) | 3.96 Billion |
| Market Forecast in 2031 (Value) | 9.37 Billion |
| Growth Rate | 18.8 |
| Years Considered | 2024-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
WHAT IS IN IT FOR YOU: NGS SERVICES MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Rest of Europe Breakdown | Country-level market sizing and growth forecasts (Switzerland, Sweden, Turkey, the Netherlands, Norway, Poland, Portugal, Romania, Denmark, Estonia, Finland, the Czech Republic, Greece, Austria, Belgium, and Russia) | Provides granular country-level insights, enabling clients to prioritize high-growth markets |
| Company Evaluation |
|
Delivers visibility into competitors, helping clients identify partners, evaluate positioning, detect market gaps for smarter collaboration, and strategic market entry decisions |
RECENT DEVELOPMENTS
- March 2026 : Illumina and Labcorp expanded their collaboration to broaden access to precision oncology testing using NGS, including distributed cancer biomarker testing, evidence generation, and development of testing solutions for unmet clinical needs.
- March 2026 : PacBio collaborated with Basecamp Research to generate large-scale environmental and host-associated metagenomic sequencing data for the Trillion Gene Atlas. The program is expected to involve approximately 100,000 deeply sequenced samples from more than 31 countries.
- March 2026 : Oxford Nanopore Technologiesand A. D. A. M. Innovations collaborated to develop and deploy nanopore-based genomic sequencing across A.D.A.M. Innovations' genetic-testing portfolio in Japan, with the aim of introducing validated clinical sequencing workflows across multiple disease areas.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
39
2
EXECUTIVE SUMMARY
43
3
PREMIUM INSIGHTS
49
4
MARKET OVERVIEW
Unlock growth by navigating NGS market dynamics and leveraging long-read sequencing opportunities.
52
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.1.1
GROWING OUTSOURCING OF NGS WORKFLOWS
4.2.1.2
EXPANSION OF POPULATION GENOMICS PROGRAMS
4.2.1.3
RISING USE OF NGS IN CLINICAL RESEARCH
4.2.2
RESTRAINTS
4.2.2.1
DECREASING COSTS OF BENCHTOP NGS SYSTEMS/SEQUENCERS
4.2.2.2
MANAGING TURNAROUND TIME AND CAPACITY UTILIZATION
4.2.3
OPPORTUNITIES
4.2.3.1
GROWING ADOPTION OF LONG-READ SEQUENCING SERVICES
4.2.3.2
RISING DEMAND FOR CUSTOMIZED NGS SERVICES
4.2.4
CHALLENGES
4.2.4.1
MANAGING, ANALYZING, AND INTERPRETING LARGE VOLUMES OF NGS DATA
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Discover how macroeconomic shifts and R&D trends reshape competitive dynamics and pricing in biotech.
60
5.1
PORTER’S FIVE FORCES ANALYSIS
5.1.1
INTENSITY OF COMPETITIVE RIVALRY
5.1.2
BARGAINING POWER OF SUPPLIERS
5.1.3
BARGAINING POWER OF BUYERS
5.1.4
THREAT OF SUBSTITUTES
5.1.5
THREAT OF NEW ENTRANTS
5.2
MACROECONOMIC OUTLOOK
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS AND FORECAST
5.2.3
R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY
5.2.4
R&D TRENDS IN GLOBAL BIOTECH INDUSTRY
5.3
VALUE CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.4.1
ROLE IN ECOSYSTEM
5.5
PRICING ANALYSIS
5.5.1
INDICATIVE SELLING PRICE, BY SERVICE TYPE, 2025
5.5.2
INDICATIVE SELLING PRICE, BY REGION, 2025
5.6
KEY CONFERENCES & EVENTS, 2026–2027
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
5.8
INVESTMENT & FUNDING SCENARIO
5.9
CASE STUDY ANALYSIS
5.9.1
COMPREHENSIVE GENOMIC PROFILING GUIDES IMMUNOTHERAPY IN CANCER OF UNKNOWN PRIMARY
5.9.2
LIQUID BIOPSY NGS IDENTIFIES RARE ALK ALTERATION AND ENABLES TARGETED THERAPY
5.10
IMPACT OF 2025 US TARIFFS—NGS SERVICES MARKET
5.10.1
INTRODUCTION
5.10.2
KEY TARIFF RATES
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRIES/REGIONS
5.10.4.1
US
5.10.4.2
EUROPE
5.10.4.3
ASIA PACIFIC
5.10.5
IMPACT ON END-USE INDUSTRIES
5.10.5.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
5.10.5.2
ACADEMIC & RESEARCH INSTITUTES
5.10.5.3
HOSPITALS & CLINICAL LABORATORIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven sequencing innovations redefine genomics with unprecedented precision and market potential.
78
6.1
TECHNOLOGY ANALYSIS
6.1.1
KEY TECHNOLOGIES
6.1.1.1
SEQUENCING BY SYNTHESIS
6.1.1.2
NANOPORE SEQUENCING
6.1.1.3
SINGLE-MOLECULE REAL-TIME SEQUENCING
6.1.2
COMPLEMENTARY TECHNOLOGIES
6.1.2.1
AUTOMATED SAMPLE PREPARATION SYSTEM
6.1.2.2
BIOINFORMATICS AND DATA ANALYSIS
6.1.2.3
MULTIPLEX PCR
6.1.3
ADJACENT TECHNOLOGIES
6.1.3.1
SINGLE-CELL SEQUENCING TECHNOLOGY
6.1.3.2
MULTI-OMICS INTEGRATION
6.1.3.3
SPATIAL GENOMICS AND TRANSCRIPTOMICS
6.2
TECHNOLOGY ROADMAP
6.3
FUTURE APPLICATIONS
6.4
IMPACT OF AI/GEN AI ON NGS SERVICES MARKET
6.4.1
TOP USE CASES AND MARKET POTENTIAL
6.4.2
BEST PRACTICES IN AI-ENABLED NGS WORKFLOWS
6.4.3
CASE STUDIES OF AI IMPLEMENTATION IN NGS SERVICES MARKET
6.4.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.4.5
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED SEQUENCING SOLUTIONS
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
Navigate global compliance intricacies to align sustainability initiatives with regional regulations.
86
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
7.1.2.1
NORTH AMERICA
7.1.2.2
EUROPE
7.1.2.3
ASIA PACIFIC
7.1.2.4
REST OF THE WORLD
7.2
SUSTAINABILITY INITIATIVES
7.3
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
7.4
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
Uncover hidden stakeholder influences and unmet needs shaping buyer decisions across industries.
95
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.2.1
KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2
KEY BUYING CRITERIA, BY END USER
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
NEXT-GENERATION SEQUENCING SERVICES MARKET, BY TYPE
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 123 Data Tables
99
9.1
INTRODUCTION
9.2
SEQUENCING SERVICES
9.2.1
EXOME & TARGETED RESEQUENCING SERVICES AND CUSTOM PANELS
9.2.1.1
ADVANCEMENTS IN TARGET ENRICHMENT TECHNOLOGIES TO DRIVE MARKET
9.2.2
RNA SEQUENCING SERVICES
9.2.2.1
LAUNCH OF RNA SERVICES AND AVAILABILITY OF DIVERSE RNA BIOINFORMATICS TOOLS TO DRIVE MARKET
9.2.3
DE NOVO SEQUENCING SERVICES
9.2.3.1
ACCURATE AND RAPID CHARACTERIZATION TO DRIVE MARKET
9.2.4
CHIP SEQUENCING SERVICES
9.2.4.1
SURGE IN DEMAND FROM ACADEMIC AND RESEARCH INSTITUTES TO DRIVE MARKET
9.2.5
WHOLE-GENOME SEQUENCING SERVICES
9.2.5.1
TECHNOLOGICAL ADVANCEMENTS IN NEXT-GENERATION SEQUENCING PRODUCTS TO DRIVE MARKET
9.2.6
METHYL SEQUENCING SERVICES
9.2.6.1
LARGE-SCALE ADOPTION IN CANCER RESEARCH TO DRIVE MARKET
9.2.7
OTHER SEQUENCING SERVICES
9.3
PRESEQUENCING SERVICES
9.3.1
LIBRARY PREPARATION & TARGET ENRICHMENT SERVICES
9.3.1.1
DEVELOPMENT OF ADVANCED LIBRARY PREPARATION SOLUTIONS TO DRIVE MARKET
9.3.2
SAMPLE PREPARATION SERVICES
9.3.2.1
APPLICABILITY IN ONCOLOGY, INFECTIOUS DISEASES, METAGENOMICS, AND EPIGENETICS TO DRIVE MARKET
9.3.3
QUALITY CONTROL SERVICES
9.3.3.1
GROWING RESEARCH ACTIVITIES USING NEXT-GENERATION SEQUENCING TECHNOLOGY TO DRIVE MARKET
9.4
BIOINFORMATICS & DATA ANALYSIS SERVICES
9.4.1
DATA ANALYSIS SERVICES
9.4.1.1
INCREASING DEMAND FOR PRECISION AND SPEED IN GENOMICS FOR CLINICAL DIAGNOSIS TO DRIVE MARKET
9.4.2
DATA VISUALIZATION & INTERPRETATION SERVICES
9.4.2.1
RISING DEMAND FOR SEQUENCING-BASED RESEARCH TO DRIVE MARKET
9.4.3
DATA STORAGE & MANAGEMENT SERVICES
9.4.3.1
NEED FOR EFFECTIVE DATA MANAGEMENT TO DRIVE MARKET
9.5
NGS PLATFORM SERVICES
9.5.1
COMPLIANCE WITH STRINGENT QUALITY AND OPERATIONAL REQUIREMENTS TO DRIVE MARKET
10
NEXT-GENERATION SEQUENCING SERVICES MARKET, BY WORKFLOW
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
159
10.1
INTRODUCTION
10.2
SEQUENCING
10.2.1
RISING DEMAND FOR SEQUENCING SERVICES AND APPLICATIONS IN CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH
10.3
PRESEQUENCING SERVICES
10.3.1
CUSTOM DEVELOPMENT OF SAMPLES FOR SEQUENCING TO BOOST MARKET GROWTH
10.4
DATA ANALYSIS SERVICES
10.4.1
RISING DEMAND FOR ADVANCED RESEARCH TO DRIVE MARKET
11
NEXT-GENERATION SEQUENCING SERVICES MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 73 Data Tables
171
11.1
INTRODUCTION
11.2
DIAGNOSTICS
11.2.1
CANCER DIAGNOSTICS
11.2.1.1
RISING DEMAND FOR TARGETED THERAPIES TO DRIVE MARKET GROWTH
11.2.2
INFECTIOUS DISEASE DIAGNOSTICS
11.2.2.1
RISING DEMAND FOR COMPREHENSIVE SEQUENCING DATA IN PATHOGEN DETECTION TO PROPEL GROWTH
11.2.3
REPRODUCTIVE HEALTH DIAGNOSTICS
11.2.3.1
HIGH DEMAND FOR PRENATAL TESTING TO DRIVE GROWTH
11.2.4
OTHER DIAGNOSTIC APPLICATIONS
11.3
DRUG DISCOVERY & DEVELOPMENT
11.3.1
PHARMACOGENOMICS
11.3.1.1
RISING USE OF NGS FOR UNDERSTANDING GENOMIC VARIANTS IN HUMANS TO DRIVE GROWTH
11.3.2
OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS
11.4
AGRICULTURE & ANIMAL RESEARCH
11.4.1
EMPHASIS ON IMPROVING CROP PRODUCTIVITY TO DRIVE ADOPTION OF NGS
11.5
OTHER APPLICATIONS
12
NEXT-GENERATION SEQUENCING SERVICES MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables
209
12.1
INTRODUCTION
12.2
ACADEMIC & RESEARCH INSTITUTES
12.2.1
GROWING RESEARCH INTENSITY TO SUPPORT MARKET GROWTH
12.3
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.3.1
RISING DEMAND FOR COMPREHENSIVE GENETIC DATA TO DRIVE GROWTH
12.4
HOSPITALS & CLINICAL LABORATORIES
12.4.1
INCREASED APPLICATION OF NGS IN DISEASE DIAGNOSTICS AND TREATMENT TO DRIVE GROWTH
12.5
OTHER END USERS
13
NEXT-GENERATION SEQUENCING SERVICES MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 17 Countries | 268 Data Tables.
225
13.1
INTRODUCTION
13.2
NORTH AMERICA
13.2.1
US
13.2.1.1
RAPID GROWTH AND ADVANCEMENTS TO LEAD MARKET
13.2.2
CANADA
13.2.2.1
INCREASING GOVERNMENT INITIATIVES IN SEQUENCING RESEARCH TO BOOST MARKET GROWTH
13.3
EUROPE
13.3.1
GERMANY
13.3.1.1
ADOPTION OF ADVANCED SEQUENCING TECHNOLOGIES TO DRIVE MARKET
13.3.2
UK
13.3.2.1
STRATEGIC INITIATIVES AND FUNDING FOR GENOMICS RESEARCH TO SUPPORT MARKET GROWTH
13.3.3
FRANCE
13.3.3.1
ROBUST GROWTH IN THE PUBLIC SECTOR FOR GENOMICS RESEARCH TO DRIVE GROWTH
13.3.4
ITALY
13.3.4.1
FAVORABLE FUNDING SCENARIO TO DRIVE ADOPTION OF ADVANCED SEQUENCING TECHNOLOGY
13.3.5
SPAIN
13.3.5.1
GROWING FOCUS ON ADVANCEMENTS IN PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
13.3.6
NETHERLANDS
13.3.6.1
WELL-ESTABLISHED RESEARCH INFRASTRUCTURE TO SUSTAIN DEMAND FOR NGS
13.3.7
REST OF EUROPE
13.4
ASIA PACIFIC
13.4.1
CHINA
13.4.1.1
EXPANSION OF INTEGRATED CLINICAL WORKFLOWS, AUTOMATION AND HIGH-THROUGHPUT SEQUENCING SERVICES DRIVES NGS SERVICES GROWTH IN CHINA
13.4.2
JAPAN
13.4.2.1
RISING NUMBER OF COLLABORATIONS IN NGS TO DRIVE MARKET
13.4.3
INDIA
13.4.3.1
EXPANSION OF INTEGRATED SEQUENCING, POPULATION GENOMICS AND SPECIALIZED BIOINFORMATICS SERVICES DRIVES GROWTH
13.4.4
AUSTRALIA
13.4.4.1
EXPANSION OF INTEGRATED SEQUENCING, LONG-READ WORKFLOWS AND SPECIALIZED BIOINFORMATICS SERVICES PROPELS MARKET
13.4.5
SOUTH KOREA
13.4.5.1
EXPANSION OF INTEGRATED CLINICAL SEQUENCING, AUTOMATED GENOMIC PRODUCTION, AND AI-ENABLED DATA ANALYSIS IS DRIVING NGS SERVICES GROWTH IN SOUTH KOREA
13.4.6
REST OF ASIA PACIFIC
13.5
LATIN AMERICA
13.5.1
BRAZIL
13.5.1.1
EXPANSION OF CLINICAL SEQUENCING INFRASTRUCTURE AND INTEGRATED GENOMIC ANALYSIS SERVICES TO BOOST MARKET
13.5.2
MEXICO
13.5.2.1
GROWING DOMESTIC SEQUENCING INFRASTRUCTURE AND CLINICAL GENOMIC ANALYSIS TO PROPEL MARKET
13.5.3
REST OF LATIN AMERICA
13.6
MIDDLE EAST
13.6.1
GCC COUNTRIES
13.6.1.1
SAUDI ARABIA
13.6.1.1.1
EXPANSION OF NATIONAL GENOMICS PROGRAMS, PRECISION MEDICINE, AND LOCALIZED SEQUENCING-TO-BIOINFORMATICS CAPABILITIES DRIVES GROWTH
13.6.1.2
UAE
13.6.1.2.1
EXPANSION OF POPULATION GENOMICS, PRECISION MEDICINE, AND INTEGRATED SEQUENCING-TO-BIOINFORMATICS WORKFLOWS IS DRIVING NGS SERVICES GROWTH IN THE UAE
13.6.1.3
REST OF GCC COUNTRIES
13.6.2
REST OF MIDDLE EAST
13.7
AFRICA
13.7.1
EXPANSION OF GENOMIC SURVEILLANCE, PRECISION MEDICINE, AND LOCALIZED SEQUENCING TO DRIVE MARKET
14
COMPETITIVE LANDSCAPE
Discover strategic insights and market dominance tactics of leading NGS service providers and emerging startups.
336
14.1
INTRODUCTION
14.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
14.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NGS SERVICES MARKET (JANUARY 2023–AUGUST 2026)
14.3
REVENUE ANALYSIS, 2021–2025
14.4
MARKET SHARE ANALYSIS, 2025
14.5
BRAND COMPARISON
14.6
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
14.6.1
STARS
14.6.2
EMERGING LEADERS
14.6.3
PERVASIVE PLAYERS
14.6.4
PARTICIPANTS
14.6.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
14.6.5.1
COMPANY FOOTPRINT
14.6.5.2
REGION FOOTPRINT
14.6.5.3
TYPE FOOTPRINT
14.6.5.4
APPLICATION FOOTPRINT
14.7
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
14.7.1
PROGRESSIVE COMPANIES
14.7.2
RESPONSIVE COMPANIES
14.7.3
DYNAMIC COMPANIES
14.7.4
STARTING BLOCKS
14.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
14.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
14.7.5.2
COMPETITIVE BENCHMARKING OF STARTUPS/SMES
14.8
COMPANY VALUATION & FINANCIAL METRICS
14.8.1
FINANCIAL METRICS
14.8.2
COMPANY VALUATION
14.9
COMPETITIVE SCENARIO
14.9.1
SERVICE LAUNCHES
14.9.2
DEALS
14.9.3
EXPANSIONS
15
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
355
15.1
KEY PLAYERS
15.1.1
ILLUMINA, INC.
15.1.1.1
BUSINESS OVERVIEW
15.1.1.2
SERVICES OFFERED
15.1.1.3
RECENT DEVELOPMENTS
15.1.1.3.1
DEALS
15.1.1.3.2
EXPANSIONS
15.1.1.4
MNM VIEW
15.1.1.4.1
KEY STRENGTHS
15.1.1.4.2
STRATEGIC CHOICES
15.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
15.1.2
THERMO FISHER SCIENTIFIC INC.
15.1.3
EUROFINS SCIENTIFIC
15.1.4
BGI GROUP
15.1.5
AZENTA US INC.
15.1.6
REVVITY
15.1.7
AGILENT TECHNOLOGIES, INC.
15.1.8
PACBIO
15.1.9
OXFORD NANOPORE TECHNOLOGIES PLC
15.1.10
F. HOFFMANN-LA ROCHE LTD.
15.1.11
LGC LIMITED
15.1.12
WUXI BIOLOGICS
15.1.13
QIAGEN
15.1.14
LABCORP
15.1.15
IQVIA
15.1.16
TWIST BIOSCIENCE
15.2
OTHER PLAYERS
15.2.1
NOVOGENE CO., LTD.
15.2.2
GENSCRIPT
15.2.3
PSOMAGEN
15.2.4
ZYMO RESEARCH CORPORATION
15.2.5
NEOGENOMICS LABORATORIES
15.2.6
FULGENT GENETICS
15.2.7
MEDGENOME
15.2.8
CD GENOMICS
15.2.9
DISCOVERY LIFE SCIENCES
15.2.10
MACROGEN, INC.
16
RESEARCH METHODOLOGY
417
16.1
RESEARCH DATA
16.1.1
SECONDARY DATA
16.1.1.1
KEY DATA FROM SECONDARY SOURCES
16.1.2
PRIMARY DATA
16.1.2.1
KEY DATA FROM PRIMARY SOURCES
16.1.2.2
KEY PRIMARY PARTICIPANTS
16.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
16.1.2.4
KEY INDUSTRY INSIGHTS
16.2
MARKET SIZE ESTIMATION
16.2.1
GLOBAL NGS SERVICES MARKET ESTIMATION, 2025
16.2.2
SEGMENTAL MARKET SIZE ESTIMATION
16.3
MARKET GROWTH RATE PROJECTIONS
16.4
DATA TRIANGULATION
16.5
FACTOR ANALYSIS
16.6
RESEARCH ASSUMPTIONS
16.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
17
APPENDIX
429
17.1
DISCUSSION GUIDE
17.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3
CUSTOMIZATION OPTIONS
17.4
RELATED REPORTS
17.5
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
NGS SERVICES MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2
NGS SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
TABLE 3
NGS SERVICES MARKET: PORTER’S FIVE FORCES
TABLE 4
NGS SERVICES MARKET: ROLE IN ECOSYSTEM
TABLE 5
INDICATIVE SELLING PRICE, BY SERVICE TYPE, 2025 (USD)
TABLE 6
INDICATIVE SELLING PRICE, BY REGION, 2025 (USD)
TABLE 7
NGS SERVICES MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2026–SEPTEMBER 2027
TABLE 8
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 9
CASE STUDIES OF AI IMPLEMENTATION IN NGS SERVICES MARKET
TABLE 10
CLIENTS’ READINESS TO ADOPT AI-INTEGRATED SEQUENCING SOLUTIONS IN NGS SERVICES MARKET
TABLE 11
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE
TABLE 16
KEY BUYING CRITERIA, BY END USER
TABLE 17
NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 18
SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 19
NORTH AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 20
EUROPE: SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 21
ASIA PACIFIC: SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 22
LATIN AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 23
MIDDLE EAST: SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 24
GCC COUNTRIES: SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 25
SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 26
EXOME & TARGETED RESEQUENCING SERVICES AND CUSTOM PANELS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 27
NORTH AMERICA: EXOME & TARGETED RESEQUENCING SERVICES AND CUSTOM PANELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 28
EUROPE: EXOME & TARGETED RESEQUENCING SERVICES AND CUSTOM PANELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 29
ASIA PACIFIC: EXOME & TARGETED RESEQUENCING SERVICES AND CUSTOM PANELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 30
LATIN AMERICA: EXOME & TARGETED RESEQUENCING SERVICES AND CUSTOM PANELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 31
MIDDLE EAST: EXOME & TARGETED RESEQUENCING SERVICES AND CUSTOM PANELS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 32
GCC COUNTRIES: EXOME & TARGETED RESEQUENCING SERVICES AND CUSTOM PANELS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 33
RNA SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 34
NORTH AMERICA: RNA SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 35
EUROPE: RNA SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 36
ASIA PACIFIC: RNA SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 37
LATIN AMERICA: RNA SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 38
MIDDLE EAST: RNA SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 39
GCC COUNTRIES: RNA SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 40
DE NOVO SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 41
NORTH AMERICA: DE NOVO SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 42
EUROPE: DE NOVO SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 43
ASIA PACIFIC: DE NOVO SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 44
LATIN AMERICA: DE NOVO SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 45
MIDDLE EAST: DE NOVO SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 46
GCC COUNTRIES: DE NOVO SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 47
CHIP SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 48
NORTH AMERICA: CHIP SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 49
EUROPE: CHIP SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 50
ASIA PACIFIC: CHIP SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 51
LATIN AMERICA: CHIP SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 52
MIDDLE EAST: CHIP SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 53
GCC COUNTRIES: CHIP SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 54
WHOLE-GENOME SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 55
NORTH AMERICA: WHOLE-GENOME SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 56
EUROPE: WHOLE-GENOME SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 57
ASIA PACIFIC: WHOLE-GENOME SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 58
LATIN AMERICA: WHOLE-GENOME SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 59
MIDDLE EAST: WHOLE-GENOME SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 60
GCC COUNTRIES: WHOLE-GENOME SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 61
METHYL SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 62
NORTH AMERICA: METHYL SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 63
EUROPE: METHYL SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 64
ASIA PACIFIC: METHYL SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 65
LATIN AMERICA: METHYL SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 66
MIDDLE EAST: METHYL SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 67
GCC COUNTRIES: METHYL SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 68
OTHER SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 69
NORTH AMERICA: OTHER SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 70
EUROPE: OTHER SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 71
ASIA PACIFIC: OTHER SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 72
LATIN AMERICA: OTHER SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 73
MIDDLE EAST: OTHER SEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 74
GCC COUNTRIES: OTHER SEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 75
PRESEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 76
NORTH AMERICA: PRESEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 77
EUROPE: PRESEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 78
ASIA PACIFIC: PRESEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 79
LATIN AMERICA: PRESEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 80
MIDDLE EAST: PRESEQUENCING SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 81
GCC COUNTRIES: PRESEQUENCING SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 82
PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 83
LIBRARY PREPARATION & TARGET ENRICHMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 84
NORTH AMERICA: LIBRARY PREPARATION & TARGET ENRICHMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 85
EUROPE: LIBRARY PREPARATION & TARGET ENRICHMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 86
ASIA PACIFIC: LIBRARY PREPARATION & TARGET ENRICHMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 87
LATIN AMERICA: LIBRARY PREPARATION & TARGET ENRICHMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 88
MIDDLE EAST: LIBRARY PREPARATION & TARGET ENRICHMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 89
GCC COUNTRIES: LIBRARY PREPARATION & TARGET ENRICHMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 90
SAMPLE PREPARATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 91
NORTH AMERICA: SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92
EUROPE: SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 93
ASIA PACIFIC: SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 94
LATIN AMERICA: SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95
MIDDLE EAST: SAMPLE PREPARATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 96
GCC COUNTRIES: SAMPLE PREPARATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 97
QUALITY CONTROL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 98
NORTH AMERICA: QUALITY CONTROL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 99
EUROPE: QUALITY CONTROL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 100
ASIA PACIFIC: QUALITY CONTROL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 101
LATIN AMERICA: QUALITY CONTROL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 102
MIDDLE EAST: QUALITY CONTROL SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 103
GCC COUNTRIES: QUALITY CONTROL SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 104
BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 105
NORTH AMERICA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 106
EUROPE: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 107
ASIA PACIFIC: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 108
LATIN AMERICA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 109
MIDDLE EAST: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 110
GCC COUNTRIES: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 111
BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 112
DATA ANALYSIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 113
NORTH AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 114
EUROPE: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 115
ASIA PACIFIC: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 116
LATIN AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 117
MIDDLE EAST: DATA ANALYSIS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 118
GCC COUNTRIES: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 119
DATA VISUALIZATION & INTERPRETATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 120
NORTH AMERICA: DATA VISUALIZATION & INTERPRETATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 121
EUROPE: DATA VISUALIZATION & INTERPRETATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 122
ASIA PACIFIC: DATA VISUALIZATION & INTERPRETATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 123
LATIN AMERICA: DATA VISUALIZATION & INTERPRETATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 124
MIDDLE EAST: DATA VISUALIZATION & INTERPRETATION SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 125
GCC COUNTRIES: DATA VISUALIZATION & INTERPRETATION SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 126
DATA STORAGE & MANAGEMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 127
NORTH AMERICA: DATA STORAGE & MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 128
EUROPE: DATA STORAGE & MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 129
ASIA PACIFIC: DATA STORAGE & MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 130
LATIN AMERICA: DATA STORAGE & MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 131
MIDDLE EAST: DATA STORAGE & MANAGEMENT SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 132
GCC COUNTRIES: DATA STORAGE & MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 133
NGS PLATFORM SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 134
NORTH AMERICA: NGS PLATFORM SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 135
EUROPE: NGS PLATFORM SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 136
ASIA PACIFIC: NGS PLATFORM SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 137
LATIN AMERICA: NGS PLATFORM SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 138
MIDDLE EAST: NGS PLATFORM SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 139
GCC COUNTRIES: NGS PLATFORM SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 140
NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 141
NGS SERVICES MARKET FOR SEQUENCING, BY REGION, 2024–2031 (USD MILLION)
TABLE 142
NORTH AMERICA: NGS SERVICES MARKET FOR SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 143
EUROPE: NGS SERVICES MARKET FOR SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 144
ASIA PACIFIC: NGS SERVICES MARKET FOR SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 145
LATIN AMERICA: NGS SERVICES MARKET FOR SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 146
MIDDLE EAST: NGS SERVICES MARKET FOR SEQUENCING, BY REGION, 2024–2031 (USD MILLION)
TABLE 147
GCC COUNTRIES: NGS SERVICES MARKET FOR SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 148
NGS SERVICES MARKET FOR PRESEQUENCING, BY REGION, 2024–2031 (USD MILLION)
TABLE 149
NORTH AMERICA: NGS SERVICES MARKET FOR PRESEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 150
EUROPE: NGS SERVICES MARKET FOR PRESEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 151
ASIA PACIFIC: NGS SERVICES MARKET FOR PRESEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 152
LATIN AMERICA: NGS SERVICES MARKET FOR PRESEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 153
MIDDLE EAST: NGS SERVICES MARKET FOR PRESEQUENCING, BY REGION, 2024–2031 (USD MILLION)
TABLE 154
GCC COUNTRIES: NGS SERVICES MARKET FOR PRESEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 155
NGS SERVICES MARKET FOR DATA ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 156
NORTH AMERICA: NGS SERVICES MARKET FOR DATA ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 157
EUROPE: NGS SERVICES MARKET FOR DATA ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 158
ASIA PACIFIC: NGS SERVICES MARKET FOR DATA ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 159
LATIN AMERICA: NGS SERVICES MARKET FOR DATA ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 160
MIDDLE EAST: NGS SERVICES MARKET FOR DATA ANALYSIS, BY REGION, 2024–2031 (USD MILLION)
TABLE 161
GCC COUNTRIES: NGS SERVICES MARKET FOR DATA ANALYSIS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 162
NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 163
NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 164
NORTH AMERICA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 165
EUROPE: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 166
ASIA PACIFIC: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 167
LATIN AMERICA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 168
MIDDLE EAST: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 169
GCC COUNTRIES: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 170
NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171
CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 172
NORTH AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 173
EUROPE: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 174
ASIA PACIFIC: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 175
LATIN AMERICA: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 176
MIDDLE EAST: CANCER DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 177
GCC COUNTRIES: CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 178
INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 179
NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 180
EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 181
ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 182
LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 183
MIDDLE EAST: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 184
GCC COUNTRIES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 185
REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 186
NORTH AMERICA: REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 187
EUROPE: REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 188
ASIA PACIFIC: REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 189
LATIN AMERICA: REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 190
MIDDLE EAST: REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 191
GCC COUNTRIES: REPRODUCTIVE HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 192
NGS SEQUENCING SERVICES MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 193
NORTH AMERICA: NGS SEQUENCING SERVICES MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 194
EUROPE: NGS SEQUENCING SERVICES MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 195
ASIA PACIFIC: NGS SEQUENCING SERVICES MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 196
LATIN AMERICA: NGS SEQUENCING SERVICES MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 197
MIDDLE EAST: NGS SEQUENCING SERVICES MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 198
GCC COUNTRIES: NGS SEQUENCING SERVICES MARKET FOR OTHER DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 199
NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 200
NORTH AMERICA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 201
EUROPE: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 202
ASIA PACIFIC: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 203
LATIN AMERICA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 204
MIDDLE EAST: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 205
GCC COUNTRIES: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 206
NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 207
PHARMACOGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 208
NORTH AMERICA: PHARMACOGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 209
EUROPE: PHARMACOGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 210
ASIA PACIFIC: PHARMACOGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 211
LATIN AMERICA: PHARMACOGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 212
MIDDLE EAST: PHARMACOGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 213
GCC COUNTRIES: PHARMACOGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 214
NGS SERVICES MARKET FOR OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 215
NORTH AMERICA: NGS SERVICES MARKET FOR OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216
EUROPE: NGS SERVICES MARKET FOR OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 217
ASIA PACIFIC: NGS SERVICES MARKET FOR OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 218
LATIN AMERICA: NGS SERVICES MARKET FOR OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 219
MIDDLE EAST: NGS SERVICES MARKET FOR OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 220
GCC COUNTRIES: NGS SERVICES MARKET FOR OTHER DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 221
NGS SERVICES MARKET FOR AGRICULTURE & ANIMAL RESEARCH, BY REGION, 2024–2031 (USD MILLION)
TABLE 222
NORTH AMERICA: NGS SERVICES MARKET FOR AGRICULTURE & ANIMAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 223
EUROPE: NGS SERVICES MARKET FOR AGRICULTURE & ANIMAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 224
ASIA PACIFIC: NGS SERVICES MARKET FOR AGRICULTURE & ANIMAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 225
LATIN AMERICA: NGS SERVICES MARKET FOR AGRICULTURE & ANIMAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 226
MIDDLE EAST: NGS SERVICES MARKET FOR AGRICULTURE & ANIMAL RESEARCH, BY REGION, 2024–2031 (USD MILLION)
TABLE 227
GCC COUNTRIES: NGS SERVICES MARKET FOR AGRICULTURE & ANIMAL RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 228
NGS SERVICES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 229
NORTH AMERICA: NGS SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 230
EUROPE: NGS SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 231
ASIA PACIFIC: NGS SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 232
LATIN AMERICA: NGS SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 233
MIDDLE EAST: NGS SERVICES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION)
TABLE 234
GCC COUNTRIES: NGS SERVICES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 235
NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 236
NGS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 237
NORTH AMERICA: NGS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 238
EUROPE: NGS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 239
ASIA PACIFIC: NGS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 240
LATIN AMERICA: NGS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 241
MIDDLE EAST: NGS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION)
TABLE 242
GCC COUNTRIES: NGS SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 243
NGS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 244
NORTH AMERICA: NGS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 245
EUROPE: NGS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 246
ASIA PACIFIC: NGS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 247
LATIN AMERICA: NGS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 248
MIDDLE EAST: NGS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 249
GCC COUNTRIES: NGS SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 250
NGS SERVICES MARKET FOR HOSPITALS & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 251
NORTH AMERICA: NGS SERVICES MARKET FOR HOSPITALS & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 252
EUROPE: NGS SERVICES MARKET FOR HOSPITALS & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 253
ASIA PACIFIC: NGS SERVICES MARKET FOR HOSPITALS & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 254
LATIN AMERICA: NGS SERVICES MARKET FOR HOSPITALS & CLINICAL LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 255
MIDDLE EAST: NGS SERVICES MARKET FOR HOSPITALS & CLINICAL LABORATORIES, BY REGION, 2024–2031 (USD MILLION)
TABLE 256
GCC COUNTRIES: NGS SERVICES MARKET FOR HOSPITALS & CLINICAL LABORATORIES, BY COUNTRY 2024–2031 (USD MILLION)
TABLE 257
NGS SERVICES MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 258
NORTH AMERICA: NGS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 259
EUROPE: NGS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 260
ASIA PACIFIC: NGS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 261
LATIN AMERICA: NGS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 262
MIDDLE EAST: NGS SERVICES MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION)
TABLE 263
GCC COUNTRIES: NGS SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 264
NGS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 265
NORTH AMERICA: NGS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 266
NORTH AMERICA: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 267
NORTH AMERICA: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 268
NORTH AMERICA: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 269
NORTH AMERICA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 270
NORTH AMERICA: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 271
NORTH AMERICA: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 272
NORTH AMERICA: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 273
NORTH AMERICA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 274
NORTH AMERICA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 275
US: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 276
US: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 277
US: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 278
US: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 279
US: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 280
US: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 281
US: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 282
US: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 283
US: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 284
CANADA: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 285
CANADA: PRESEQUENCING SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 286
CANADA: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 287
CANADA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 288
CANADA: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 289
CANADA: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 290
CANADA: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 291
CANADA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 292
CANADA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 293
EUROPE: NGS SERVICES MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 294
EUROPE: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 295
EUROPE: PRESEQUENCING SERVICES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 296
EUROPE: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 297
EUROPE: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 298
EUROPE: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 299
EUROPE: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 300
EUROPE: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 301
EUROPE: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 302
EUROPE: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 303
GERMANY: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 304
GERMANY: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 305
GERMANY: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 306
GERMANY: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 307
GERMANY: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 308
GERMANY: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 309
GERMANY: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 310
GERMANY: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 311
GERMANY: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 312
UK: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 313
UK: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 314
UK: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 315
UK: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 316
UK: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 317
UK: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 318
UK: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 319
UK: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 320
UK: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 321
FRANCE: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 322
FRANCE: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 323
FRANCE: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 324
FRANCE: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 325
FRANCE: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 326
FRANCE: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 327
FRANCE: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 328
FRANCE: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 329
FRANCE: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 330
ITALY: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 331
ITALY: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 332
ITALY: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 333
ITALY: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 334
ITALY: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 335
ITALY: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 336
ITALY: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 337
ITALY: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 338
ITALY: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 339
SPAIN: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 340
SPAIN: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 341
SPAIN: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 342
SPAIN: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 343
SPAIN: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 344
SPAIN: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 345
SPAIN: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 346
SPAIN: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 347
SPAIN: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 348
NETHERLANDS: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 349
NETHERLANDS: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 350
NETHERLANDS: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 351
NETHERLANDS: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 352
NETHERLANDS: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 353
NETHERLANDS: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 354
NETHERLANDS: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 355
NETHERLANDS: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 356
NETHERLANDS: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 357
REST OF EUROPE: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 358
REST OF EUROPE: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 359
REST OF EUROPE: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 360
REST OF EUROPE: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 361
REST OF EUROPE: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 362
REST OF EUROPE: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 363
REST OF EUROPE: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 364
REST OF EUROPE: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 365
REST OF EUROPE: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 366
ASIA PACIFIC: NGS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 367
ASIA PACIFIC: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 368
ASIA PACIFIC: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 369
ASIA PACIFIC: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 370
ASIA PACIFIC: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 371
ASIA PACIFIC: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 372
ASIA PACIFIC: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 373
ASIA PACIFIC: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 374
ASIA PACIFIC: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 375
ASIA PACIFIC: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 376
CHINA: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 377
CHINA: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 378
CHINA: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 379
CHINA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 380
CHINA: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 381
CHINA: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 382
CHINA: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 383
CHINA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 384
CHINA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 385
JAPAN: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 386
JAPAN: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 387
JAPAN: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 388
JAPAN: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 389
JAPAN: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 390
JAPAN: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 391
JAPAN: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 392
JAPAN: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 393
JAPAN: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 394
INDIA: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 395
INDIA: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 396
INDIA: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 397
INDIA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 398
INDIA: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 399
INDIA: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 400
INDIA: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 401
INDIA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 402
INDIA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 403
AUSTRALIA: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 404
AUSTRALIA: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 405
AUSTRALIA: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 406
AUSTRALIA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 407
AUSTRALIA: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 408
AUSTRALIA: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 409
AUSTRALIA: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 410
AUSTRALIA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 411
AUSTRALIA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 412
SOUTH KOREA: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 413
SOUTH KOREA: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 414
SOUTH KOREA: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 415
SOUTH KOREA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 416
SOUTH KOREA: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 417
SOUTH KOREA: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 418
SOUTH KOREA: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 419
SOUTH KOREA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 420
SOUTH KOREA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 421
REST OF ASIA PACIFIC: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 422
REST OF ASIA PACIFIC: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 423
REST OF ASIA PACIFIC: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 424
REST OF ASIA PACIFIC: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 425
REST OF ASIA PACIFIC: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 426
REST OF ASIA PACIFIC: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 427
REST OF ASIA PACIFIC: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 428
REST OF ASIA PACIFIC: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 429
REST OF ASIA PACIFIC: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 430
LATIN AMERICA: NGS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 431
LATIN AMERICA: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 432
LATIN AMERICA: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 433
LATIN AMERICA: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 434
LATIN AMERICA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 435
LATIN AMERICA: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 436
LATIN AMERICA: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 437
LATIN AMERICA: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 438
LATIN AMERICA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 439
LATIN AMERICA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 440
BRAZIL: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 441
BRAZIL: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 442
BRAZIL: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 443
BRAZIL: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 444
BRAZIL: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 445
BRAZIL: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 446
BRAZIL: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 447
BRAZIL: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 448
BRAZIL: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 449
MEXICO: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 450
MEXICO: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 451
MEXICO: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 452
MEXICO: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 453
MEXICO: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 454
MEXICO: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 455
MEXICO: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 456
MEXICO: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 457
MEXICO: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 458
REST OF LATIN AMERICA: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 459
REST OF LATIN AMERICA: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 460
REST OF LATIN AMERICA: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 461
REST OF LATIN AMERICA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 462
REST OF LATIN AMERICA: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 463
REST OF LATIN AMERICA: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 464
REST OF LATIN AMERICA: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 465
REST OF LATIN AMERICA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 466
REST OF LATIN AMERICA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 467
MIDDLE EAST: NGS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 468
MIDDLE EAST: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 469
MIDDLE EAST: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 470
MIDDLE EAST: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 471
MIDDLE EAST: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 472
MIDDLE EAST: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 473
MIDDLE EAST: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 474
MIDDLE EAST: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 475
MIDDLE EAST: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 476
MIDDLE EAST: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 477
GCC COUNTRIES: NGS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 478
GCC COUNTRIES: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 479
GCC COUNTRIES: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 480
GCC COUNTRIES: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 481
GCC COUNTRIES: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 482
GCC COUNTRIES: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 483
GCC COUNTRIES: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 484
GCC COUNTRIES: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 485
GCC COUNTRIES: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 486
GCC COUNTRIES: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 487
SAUDI ARABIA: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 488
SAUDI ARABIA: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 489
SAUDI ARABIA: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 490
SAUDI ARABIA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 491
SAUDI ARABIA: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 492
SAUDI ARABIA: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 493
SAUDI ARABIA: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 494
SAUDI ARABIA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 495
SAUDI ARABIA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 496
UAE: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 497
UAE: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 498
UAE: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 499
UAE: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 500
UAE: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 501
UAE: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 502
UAE: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 503
UAE: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 504
UAE: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 505
REST OF GCC COUNTRIES: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 506
REST OF GCC COUNTRIES: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 507
REST OF GCC COUNTRIES: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 508
REST OF GCC COUNTRIES: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 509
REST OF GCC COUNTRIES: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 510
REST OF GCC COUNTRIES: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 511
REST OF GCC COUNTRIES: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 512
REST OF GCC COUNTRIES: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 513
REST OF GCC COUNTRIES: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 514
REST OF MIDDLE EAST: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 515
REST OF MIDDLE EAST: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 516
REST OF MIDDLE EAST: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 517
REST OF MIDDLE EAST: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 518
REST OF MIDDLE EAST: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 519
REST OF MIDDLE EAST: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 520
REST OF MIDDLE EAST: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 521
REST OF MIDDLE EAST: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 522
REST OF MIDDLE EAST: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 523
AFRICA: NGS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 524
AFRICA: PRESEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 525
AFRICA: SEQUENCING SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 526
AFRICA: BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET, BY TYPE, 2024–2031 (USD MILLION)
TABLE 527
AFRICA: NGS SERVICES MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
TABLE 528
AFRICA: NGS SERVICES MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 529
AFRICA: NGS SERVICES MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
TABLE 530
AFRICA: NGS SERVICES MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 531
AFRICA: NGS SERVICES MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 532
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN NGS SERVICES MARKET (JANUARY 2023—AUGUST 2026)
TABLE 533
NGS SERVICES MARKET: DEGREE OF COMPETITION
TABLE 534
NGS SERVICES MARKET: REGION FOOTPRINT
TABLE 535
NGS SERVICES MARKET: TYPE FOOTPRINT
TABLE 536
NGS SERVICES MARKET: APPLICATION FOOTPRINT
TABLE 537
NGS SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 538
NGS SERVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
TABLE 539
NGS SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2023–AUGUST 2026
TABLE 540
NGS SERVICES MARKET: DEALS, JANUARY 2023–AUGUST 2026
TABLE 541
NGS SERVICES MARKET: EXPANSIONS, JANUARY 2023–AUGUST 2026
TABLE 542
ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 543
ILLUMINA, INC.: SERVICES OFFERED
TABLE 544
ILLUMINA, INC.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 545
ILLUMINA, INC.: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 546
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 547
THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED
TABLE 548
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 549
EUROFINS SCIENTIFIC: COMPANY OVERVIEW
TABLE 550
EUROFINS SCIENTIFIC: SERVICES OFFERED
TABLE 551
EUROFINS SCIENTIFIC: SERVICE LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 552
BGI GROUP: COMPANY OVERVIEW
TABLE 553
BGI GROUP: SERVICES OFFERED
TABLE 554
BGI GROUP: SERVICE LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 555
BGI GROUP: DEALS, JANUARY 2023-AUGUST 2026
TABLE 556
BGI GROUP: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 557
AZENTA US INC.: COMPANY OVERVIEW
TABLE 558
AZENTA US INC.: SERVICES OFFERED
TABLE 559
AZENTA US INC.: SERVICE LAUNCHES, JANUARY 2023-AUGUST 2026
TABLE 560
AZENTA US INC.: DEALS, JANUARY 2023-AUGUST 2026
TABLE 561
AZENTA US INC.: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 562
REVVITY: COMPANY OVERVIEW
TABLE 563
REVVITY: SERVICES OFFERED
TABLE 564
REVVITY: DEALS, JANUARY 2023-AUGUST 2026
TABLE 565
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 566
AGILENT TECHNOLOGIES, INC.: SERVICES OFFERED
TABLE 567
PACBIO: COMPANY OVERVIEW
TABLE 568
PACBIO: SERVICES OFFERED
TABLE 569
PACBIO: DEALS, JANUARY 2023-AUGUST 2026
TABLE 570
PACBIO: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 571
OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
TABLE 572
OXFORD NANOPORE TECHNOLOGIES PLC: SERVICES OFFERED
TABLE 573
OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2023-AUGUST 2026
TABLE 574
OXFORD NANOPORE TECHNOLOGIES PLC: EXPANSIONS, JANUARY 2023-AUGUST 2026
TABLE 575
F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
TABLE 576
F. HOFFMANN-LA ROCHE LTD.: SERVICES OFFERED
TABLE 577
LGC LIMITED: COMPANY OVERVIEW
TABLE 578
LGC LIMITED: SERVICES OFFERED
TABLE 579
LGC LIMITED: DEALS, JANUARY 2023-AUGUST 2026
TABLE 580
WUXI BIOLOGICS: COMPANY OVERVIEW
TABLE 581
WUXI BIOLOGICS: SERVICES OFFERED
TABLE 582
QIAGEN: COMPANY OVERVIEW
TABLE 583
QIAGEN: SERVICES OFFERED
TABLE 584
LABCORP: COMPANY OVERVIEW
TABLE 585
LABCORP: SERVICES OFFERED
TABLE 586
LABCORP: DEALS, JANUARY 2023-AUGUST 2026
TABLE 587
IQVIA: COMPANY OVERVIEW
TABLE 588
IQVIA: SERVICES OFFERED
TABLE 589
IQVIA: DEALS, JANUARY 2023-AUGUST 2026
TABLE 590
TWIST BIOSCIENCE: COMPANY OVERVIEW
TABLE 591
TWIST BIOSCIENCE: SERVICES OFFERED
TABLE 592
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 593
RISK ASSESSMENT
LIST OF FIGURES
FIGURE 1
NGS SERVICES MARKET SEGMENTATION AND REGIONS CONSIDERED
FIGURE 2
NGS SERVICES MARKET: YEARS CONSIDERED
FIGURE 3
MARKET SCENARIO
FIGURE 4
GLOBAL NGS SERVICES MARKET, 2024–2031
FIGURE 5
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NGS SERVICES MARKET, 2023–2026
FIGURE 6
DISRUPTIONS INFLUENCING GROWTH OF NGS SERVICES MARKET
FIGURE 7
HIGH-GROWTH SEGMENTS IN NGS SERVICES MARKET, 2026–2031
FIGURE 8
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NGS SERVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
FIGURE 9
GROWING OUTSOURCING OF NGS WORKFLOWS TO DRIVE MARKET GROWTH
FIGURE 10
SEQUENCING SERVICES ACCOUNTED FOR LARGEST SHARE IN NORTH AMERICA IN 2025
FIGURE 11
ASIA PACIFIC COUNTRIES TO REGISTER HIGH GROWTH DURING FORECAST PERIOD
FIGURE 12
SEQUENCING TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 13
NGS SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14
NGS SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15
NGS SERVICES MARKET: VALUE CHAIN ANALYSIS
FIGURE 16
NGS SERVICES MARKET: ECOSYSTEM ANALYSIS
FIGURE 17
NGS SERVICES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
FIGURE 18
FUNDING AND DEALS IN NGS SERVICES MARKET, 2023–2025 (USD MILLION)
FIGURE 19
IMPACT OF AI/GEN AI ON NGS SERVICES MARKET
FIGURE 20
INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE
FIGURE 21
KEY BUYING CRITERIA, BY END USER
FIGURE 22
NORTH AMERICA: NGS SERVICES MARKET SNAPSHOT
FIGURE 23
ASIA PACIFIC: NGS SERVICES MARKET SNAPSHOT
FIGURE 24
REVENUE ANALYSIS OF KEY PLAYERS IN NGS SERVICES MARKET, 2021–2025 (USD MILLION)
FIGURE 25
MARKET SHARE ANALYSIS, 2025
FIGURE 26
NGS SERVICES MARKET: BRAND COMPARATIVE ANALYSIS
FIGURE 27
NGS SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 28
NGS SERVICES MARKET: COMPANY FOOTPRINT
FIGURE 29
NGS SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 30
EV/EBITDA OF KEY VENDORS
FIGURE 31
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 32
ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
FIGURE 33
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
FIGURE 34
EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
FIGURE 35
AZENTA US INC.: COMPANY SNAPSHOT (2025)
FIGURE 36
REVVITY: COMPANY SNAPSHOT (2025)
FIGURE 37
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
FIGURE 38
PACBIO: COMPANY SNAPSHOT (2025)
FIGURE 39
OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025)
FIGURE 40
F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
FIGURE 41
LGC LIMITED: COMPANY SNAPSHOT (2024)
FIGURE 42
WUXI BIOLOGICS: COMPANY SNAPSHOT (2025)
FIGURE 43
QIAGEN: COMPANY SNAPSHOT (2025)
FIGURE 44
LABCORP: COMPANY SNAPSHOT (2025)
FIGURE 45
IQVIA: COMPANY SNAPSHOT (2025)
FIGURE 46
TWIST BIOSCIENCE: COMPANY SNAPSHOT (2025)
FIGURE 47
NGS SERVICES MARKET: RESEARCH DESIGN
FIGURE 48
NGS SERVICES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 49
NGS SERVICES MARKET: INSIGHTS FROM PRIMARIES
FIGURE 50
GLOBAL NGS SERVICES MARKET ESTIMATION, 2025
FIGURE 51
NGS SERVICES MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025)
FIGURE 52
ILLUSTRATIVE EXAMPLE OF ILLUMINA, INC.: REVENUE ANALYSIS (2025)
FIGURE 53
SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
FIGURE 54
NGS SERVICES MARKET: CAGR PROJECTIONS
FIGURE 55
NGS SERVICES MARKET: DATA TRIANGULATION
Methodology
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global NGS services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with primary research inputs to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the NGS services market. The secondary sources used for this study include Centers for Disease Control and Prevention (CDC), National Human Genome Research Institute (NHGRI), International Chromosome and Genome Society (ICGS), European Society of Human Genetics (ESHG), Centre for Cellular & Molecular Biology (CCMB), European Medicines Agency (EMA), Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI), World Health Organization (WHO), and United States Food & Drug Administration (USFDA). This also includes academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations, among others. Secondary data were collected and analyzed to determine the overall size of the global NGS services market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
In this report, NGS refers to non-Sanger-based, high-throughput DNA and RNA sequencing technologies. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing. The NGS services market encompasses outsourced sequencing and associated laboratory and bioinformatics services provided for comprehensive genomic and transcriptomic analysis. Services include pre-sequencing/sample preparation, library preparation, sequencing, data processing, bioinformatics analysis, and interpretation. The market covers sequencing services such as whole-genome sequencing (WGS), whole-exome sequencing (WES), RNA sequencing, targeted sequencing, and metagenomics/16S sequencing, supporting applications across oncology, infectious disease research, reproductive health, drug discovery, and other life science and clinical research areas.
NGS Services Market : Top-Down and Bottom-Up Approach
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Data center immersion cooling fluids are specialized liquids designed to efficiently dissipate heat from IT equipment by directly submerging electronic components in a thermally conductive but electrically non- conductive liquid. These fluids are crucial in immersion cooling technology, which offers higher energy efficiency, improved thermal management, and reduced operational costs compared to traditional air- based cooling systems. There are three major types of data center immersion cooling fluids: mineral oil- based, fluorocarbon-based, and synthetic fluids. Single-phase cooling and two-phase cooling are the two primary technologies used in data center immersion cooling. Single-phase cooling involves submerging IT equipment in a fluid that remains in a liquid state while absorbing heat. The heated fluid is then circulated through heat exchangers to dissipate the heat before being recirculated. Two-phase cooling, on the other hand, utilizes a fluid that undergoes a phase change, evaporating into vapor upon absorbing heat. The vapor is then condensed back into liquid form through a cooling system. These fluids play a crucial role in efficient thermal management, energy savings, sustainability, and hardware longevity, eliminating the need for extensive air conditioning while reducing carbon footprints.
Key Stakeholders
- Pharmaceutical & biotechnology companies
- Hospitals & clinical laboratories
- Academic & research institutes
- Contract research organizations (CROs)
- NGS sequencing service providers
- Genomics & bioinformatics companies
- Life science research organizations
- Government genomics programs & public health agencies
- Venture capitalists & investors
- Market research & consulting firms
- Medical institutions & universities
- Regulatory authorities
Report Objectives
- To define, describe, and forecast the NGS services market based on type, workflow, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall NGS services market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the NGS services market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as service launches, acquisitions, expansions, agreements, partnerships, and collaborations in the NGS services market
- To benchmark players within the NGS services market using the ‘Company Evaluation Matrix’ framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Customization Options
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
The following customization options are available for the report:
- Additional country-level analysis of the data center immersion cooling fluids market
- Profiling of additional market players (up to 5)
Geographical Analysis
- Further breakdown of the Rest of Europe NGS services market, by country
- Further breakdown of the Rest of Asia Pacific NGS services market, by country
- Further breakdown of the Rest of Latin America NGS services market, by country
- Further breakdown of the Rest of Middle East NGS services market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Fact checked
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the NGS Services Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
- Canada Next-Generation Sequencing (NGS) Services Market
- Germany Next-Generation Sequencing (NGS) Services Market
- France Next-Generation Sequencing (NGS) Services Market
- China Next-Generation Sequencing (NGS) Services Market
- Japan Next-Generation Sequencing (NGS) Services Market
- India Next-Generation Sequencing (NGS) Services Market
- U.S. Next-Generation Sequencing (NGS) Services Market
- Roe Next-Generation Sequencing (NGS) Services Market
- U.K. Next-Generation Sequencing (NGS) Services Market
- Roapac Next-Generation Sequencing (NGS) Services Market
Growth opportunities and latent adjacency in NGS Services Market